Yahoo Finance

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

ArriVent BioPharma Reports Promising 16-Month Median Progression-Free Survival for Firmonertinib in First-Line NSCLC Patients with EGFR PACC Mutations

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
ascopubs.org

ALPACCA: Phase 3 trial of firmonertinib vs investigator’s choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha ...

A randomized phase III trial of chemo-immunotherapy vs immunotherapy alone for the vulnerable older adult with advanced non–small cell lung cancer: The ACHIEVE study—ECOG-ACRIN EA5221. This is an ASCO ...
Hosted on MSN

Firmonertinib trial aims to crack a long-standing lung cancer treatment gap

NEWTOWN SQUARE, PA — ArriVent BioPharma has dosed the first patient in a global Phase 3 study that could reshape first-line treatment for a small but hard-to-treat group of lung cancer patients. The ...
Nasdaq

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...